All News

A phase 1 trial by showed that decitabine with ruxolitinib was generally well tolerated and displayed promising clinical efficacy in patients with accelerated or blast-phase myeloproliferative neoplasms (MPN-AP/BP).

With everyone carrying a smartphone, there's no reason why digital health tools and apps cannot be leveraged to hold at-risk patients accountable for cardiovascular health.

As expected, California and 16 other states defending the Affordable Care Act (ACA) in a federal lawsuit announced they will appeal last month’s ruling by a Texas judge that declared the ACA unconstitutional.

Assessing the alternation of first-line antibiotics to avoid antibiotic resistance, researchers have determined that the strategy results in an increase in heterogeneity without increasing mortality.

Bristol-Myers Squibb (BMS) announced that it will be acquiring Celgene for $74 billion; Congress has confirmed the Trump administration's nominees for science advisor and drug czar; and drugmakers kicked off 2019 with drug price hikes.

An evaluation of cognitive function measurements, performance in daily activities, and the perception of cognitive functions in patients with multiple sclerosis (MS) found caregiver perceptions more closely correlate with the test measurements than patient perceptions.

The FDA has approved Stemline Therapeutics’ tagraxofusp-erzs (Elzonris), the first drug approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years or older.

Quality of life (QOL) in at-risk individuals starting pre-exposure prophylaxis (PrEP) for HIV prevention is similar to that in the general population and is maintained over time.

A woman's risk of later pelvic floor disorders is strongly associated with how her first infant is delivered, according to a recent study.

While low-grade adverse events may not be providers’ primary reporting focus, accumulated low-level toxicities have the potential to reduce patients’ quality of life.

The federal judge who ruled last month that the Affordable Care Act (ACA) was invalid issued an order over the weekend that the law will remain in effect pending appeal; pharmacies and businesses with pharmacies in New York City will no longer be allowed to sell cigarettes and other tobacco products; a federal judge has blocked the administration's cut to the 340B program.

This year, The American Journal of Managed Care® asked readers for the first time who they thought was the most influential person in healthcare. We provided some options in the poll, but we also gave readers the opportunity to write in answers, which resulted in answers like Steve Jobs of Apple, who passed away in 2011.

Here are the top 5 articles for the month of December.

The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, which reauthorizes a sickle cell disease prevention and treatment program and provides grants for research, surveillance, prevention, and treatment of heritable blood disorders, has passed Congress and been signed into law.

Patients with allergies to birch pollen who took drops of birch pollen extract under the tongue for 3 to 6 months were able to reduce their symptoms and improve their quality of life.

A genetic risk variant, rs7665090G, located near NFKB1, on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis (MS), according to the results of a recent study.

Children with Hodgkin lymphoma who are treated during childhood and survive to adulthood have higher incidence rates of breast, lung, colorectal, and thyroid cancer than the general population, according to a recent study.

As the US healthcare system continues to go through major shifts in policy and care delivery, 2018 saw several trends that remained prevalent throughout the year and will likely have significant implications for 2019.

Patients with multiple sclerosis (MS) who are stable on an interferon β (INFβ) should remain on that therapy rather than switching to another INFβ, according to a study in ClinicoEconomics and Outcomes Research.

Researchers have found that sleep disorders, especially insomnia, can impact the prevalence of migraine.

Patients with prognostic characteristics including higher-grade tumors, progesterone receptor (PgR)–negative tumors, liver metastases, and shorter treatment-free intervals derived a greater benefit from the addition of abemaciclib to endocrine therapy (ET) compared with ET alone, according to a recent study.

Despite a meaningful survival, neutropenia is independently associated with poor outcomes among critically ill patients with cancer, according to a new study. However, neutropenia was no longer significantly associated with outcome in patients treated with granulocyte colony-stimulating factor (G-CSF), suggesting a beneficial impact of the treatment.

Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.

This year, some of the most-read peer-reviewed research published in The American Journal of Managed Care® (AJMC®) explored cost-saving models of care, the benefits and hazards of health information technology, effects of incorporating Choosing Wisely principles into clinical decision support tools, and more.

The Commonwealth Fund report compared the status of health and healthcare for women in the United States to that of 10 other wealthy countries, including the United Kingdom, Canada, Germany, and Australia.

A new poll has found that most Americans support gene editing that is used to protect babies against diseases; Maine’s incoming governor, a Democrat, may be able to ignore the Medicaid work requirements the federal government just approved for the outgoing Republican governor; the new trade agreement between the United States, Canada, and Mexico includes language that could delay cheaper generics from reaching patients.